Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,350.00+0.56%ETH$2,434.62+1.18%GOLD$4,361.80-0.59%OIL$100.73-1.66%
Smart Investors Daily
OR

NYSE · ORN

Orion Group Holdings, Inc.

Industrials · Engineering & Construction

$9.12

Up+$0.06 (+0.66%)

Updated Sep 17, 2026, 10:41 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
466.24M
P/E ratio
48.72
Dividend yield
0.00%
52-week range
$8.67 – $17.40
Volume
490.25K
Avg. volume
351.9K

Price performance

ORN price history

1M range · 20 trading sessions · Daily adjusted prices

ORN closed at $9.12 after 20 trading sessions, down 5.10% for the selected period.

Last close
$9.12
Period change
-5.10%
Period low
$9.01
Period high
$9.73
Daily close
View OHLC price history
ORN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$9.23$9.32$9.06$9.12490.25K
Sep 15, 2026$9.06$9.138$8.9401$9.06330.82K
Sep 14, 2026$9.10$9.15$8.93$9.01305.15K
Sep 11, 2026$9.21$9.40$9.1453$9.36439.07K
Sep 10, 2026$9.00$9.21$8.90$9.06306.78K
Sep 9, 2026$9.15$9.48$8.96$9.09331.27K
Sep 8, 2026$9.28$9.36$9.1736$9.23224.17K
Sep 4, 2026$9.13$9.35$9.13$9.28431.31K
Sep 3, 2026$9.22$9.22$9.00$9.15343.13K
Sep 2, 2026$9.10$9.49$9.051$9.08339.8K
Sep 1, 2026$9.26$9.4466$9.02$9.05330.82K
Aug 31, 2026$9.30$9.46$9.20$9.40361.9K
Aug 28, 2026$9.68$9.70$9.22$9.27312.7K
Aug 27, 2026$9.41$9.75$9.40$9.73345.4K
Aug 26, 2026$9.28$9.41$9.20$9.33379.92K
Aug 25, 2026$9.32$9.395$9.09$9.33356.48K
Aug 24, 2026$9.26$9.295$9.04$9.10298.79K
Aug 21, 2026$9.24$9.33$8.97$9.27400.42K
Aug 20, 2026$9.49$9.665$9.065$9.18377.93K
Aug 19, 2026$9.67$9.68$9.44$9.61428.99K

Latest ORN news

The latest Smart Investors Daily articles mentioning ORN.

Stock researchCompany · Overview

ORN research

Overview

Company profile and research snapshot.

Company profile

Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar and mesh across the light commercial, structural and other associated business areas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.50
Implied upside
—
Analysts
8
ORN recent ratings
DateFirmRatingTarget
Jul 7, 2026OppenheimerOutperform—
Jun 2, 2026Freedom BrokerBuy—
May 15, 2026JP MorganOverweight—
Mar 5, 2026B. Riley SecuritiesBuy—
Feb 10, 2026Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

ORYZON to Participate in Upcoming Events in September and October

MADRID and CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: HC Wainwright 28th Annual Global Investment Conference 2026, September 14-16Location: Lotte New York Palace Hotel, New York, United StatesPresentation date and time: September 15, 10:30 am ET European Main MidCap Event

Yahoo · Aug 31, 2026

ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib

Iadademstat is under clinical development in acute myeloid leukemia (AML), including in combination with gilteritinib in the Phase Ib FRIDA trial in patients with FLT3-mutated relapsed/refractory (R/R) AML FRIDA data presented at EHA-2026 showed a high composite complete remission (CRc) rate of 67% in heavily pretreated FLT3-mutated R/R AML patients, together with a favorable safety profile MADRID and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By